Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7674479 | ALMATICA | Sustained-release bupropion and bupropion/mecamylamine tablets |
Jun, 2027
(3 years from now) |
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 10 November, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8333992 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
US8192756 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
US8252332 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
US7731989 | ALMATICA | Gastric retained gabapentin dosage form |
Oct, 2022
(11 months ago) | |
US7438927 | ALMATICA | Methods of treatment using a gastric retained gabapentin dosage |
Feb, 2024
(4 months from now) |
Drugs and Companies using GABAPENTIN ingredient
Market Authorisation Date: 28 January, 2011
Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8999393 | ALMATICA | Sustained release formulations of lorazepam |
Jan, 2034
(10 years from now) |
Drugs and Companies using LORAZEPAM ingredient
Market Authorisation Date: 27 August, 2021
Treatment: Once daily treatment of anxiety disorder in adults
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(6 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(4 years from now) |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic